title: Ð Ð°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ° Ð¼ÐµÑÐ¾Ð´Ð¸ÐºÐ¸ Ð³ÐµÐ½Ð¾ÑÐ¸Ð¿Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð¼ÑÑÐ°ÑÐ¸Ð¹ Ð³ÐµÐ½Ð¾Ð² XRCC2, CHEK2, BLM, GPRC5A Ð¸ NBS1 Ñ Ð¿Ð¾ÑÐ¾Ð¼ÑÑÐ²Ð° ÑÑÐ°Ð½ÑÐ³ÐµÐ½Ð½ÑÑ Ð¼ÑÑÐµÐ¹, Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÑ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ ÑÐµÑ Ð½Ð¾Ð»Ð¾Ð³Ð¸Ð¸ CRISPR/Cas9
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Development of a method for genotyping mutations in the XRCC2, CHEK2, BLM, GPRC5A, and NBS1 genes in the offspring of transgenic mice obtained using CRISPR/Cas9 technology
Creators: name: ÐÑÑÐ°Ð´Ð½Ð¾Ð²Ð°, ÐÐºÐ°ÑÐµÑÐ¸Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: Ð¾Ð½ÐºÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¾Ðµ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ðµ
Ð³ÐµÐ½Ð¾ÑÐ¸Ð¿Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ
Ð¼ÑÑÐ°ÑÐ¸Ð¸
Ð¿Ð¾Ð»Ð¸Ð¼ÐµÑÐ°Ð·Ð½Ð°Ñ ÑÐµÐ¿Ð½Ð°Ñ ÑÐµÐ°ÐºÑÐ¸Ñ Ð² ÑÐµÐ¶Ð¸Ð¼Ðµ ÑÐµÐ°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð²ÑÐµÐ¼ÐµÐ½Ð¸
ÑÑÐ°Ð½ÑÐ³ÐµÐ½Ð½ÑÐµ Ð¼ÑÑÐ¸
CRISPR/Cas9
oncological disease
genotyping
mutation
real-time polymerase chain reaction
transgenic mice

description: ÐÐ°ÑÐ»ÐµÐ´ÑÑÐ²ÐµÐ½Ð½ÑÐµ ÑÐ°ÐºÑÐ¾ÑÑ Ð¸Ð³ÑÐ°ÑÑ Ð²Ð°Ð¶Ð½ÑÑ ÑÐ¾Ð»Ñ Ð² ÑÐ°Ð·Ð²Ð¸ÑÐ¸Ð¸ Ð¾Ð½ÐºÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ñ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ð¹. ÐÐ·Ð²ÐµÑÑÐ½Ð¾, ÑÑÐ¾ Ð²ÑÐ¾Ð¶Ð´ÐµÐ½Ð½ÑÐµ Ð¼ÑÑÐ°ÑÐ¸Ð¹ Ð³ÐµÐ½Ð¾Ð² XRCC2, CHEK2, BLM, GPRC5A Ð¸ NBS1 Ð°ÑÑÐ¾ÑÐ¸Ð¸ÑÐ¾Ð²Ð°Ð½Ñ Ñ Ð¿Ð¾Ð²ÑÑÐµÐ½Ð½ÑÐ¼ ÑÐ¸ÑÐºÐ¾Ð¼ Ð¸Ñ ÑÐ°Ð·Ð²Ð¸ÑÐ¸Ñ. ÐÐ»Ñ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ ÑÐ¾Ð»Ð¸ Ð¼ÑÑÐ°ÑÐ¸Ð¹ ÑÑÐ¸Ñ Ð³ÐµÐ½Ð¾Ð² Ð±ÑÐ» Ð¿ÑÐµÐ´Ð»Ð¾Ð¶ÐµÐ½ Ð¿Ð¾Ð´ÑÐ¾Ð´, Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð½ÑÐ¹ Ð½Ð° ÑÐ¾Ð·Ð´Ð°Ð½Ð¸Ð¸ Ð»Ð¸Ð½Ð¸Ð¸ Ð³ÐµÐ½Ð¾Ð¼Ð¾Ð´Ð¸ÑÐ¸ÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½ÑÑ Ð¼ÑÑÐµÐ¹ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ ÑÐµÑÐ½Ð¾Ð»Ð¾Ð³Ð¸Ð¸ CRISPR/Cas9. ÐÐ°Ð¶Ð½ÑÐ¹ ÑÑÐ°Ð¿ ÑÐ°ÐºÐ¾Ð³Ð¾ Ð¿Ð¾Ð´ÑÐ¾Ð´Ð° - Ð³ÐµÐ½Ð¾ÑÐ¸Ð¿Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÑ Ð¶Ð¸Ð²Ð¾ÑÐ½ÑÑ Ð´Ð»Ñ ÑÐ¾ÑÐ¼Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ°Ð»ÑÐ½ÑÑ Ð³ÑÑÐ¿Ð¿ Ð¸ Ð¿Ð¾ÑÐ»ÐµÐ´ÑÑÑÐµÐ³Ð¾ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ° Ð¿Ð¾ Ð¸Ð½Ð´ÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½Ð¾Ð¼Ñ Ð¾Ð½ÐºÐ¾Ð³ÐµÐ½ÐµÐ·Ñ. Ð¦ÐµÐ»Ñ ÑÐ°Ð±Ð¾ÑÑ - ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ° Ð¼ÐµÑÐ¾Ð´Ð¸ÐºÐ¸ Ð´Ð»Ñ Ð³ÐµÐ½Ð¾ÑÐ¸Ð¿Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ ÑÑÐ°Ð½ÑÐ³ÐµÐ½Ð½ÑÑ Ð¼ÑÑÐµÐ¹ Ð¸ Ð¸Ñ Ð¿Ð¾ÑÐ¾Ð¼ÑÑÐ²Ð° Ð´Ð»Ñ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð¼ÑÑÐ°ÑÐ¸Ð¹ Ð³ÐµÐ½Ð¾Ð² XRCC2, CHEK2, BLM, GPRC5A Ð¸ NBS1, Ð¿ÑÐ¾ÑÐ²Ð»ÑÑÑÐ¸ÑÑÑ Ð² Ð²Ð¸Ð´Ðµ Ð³ÐµÐ½Ð½ÑÑ Ð²Ð°ÑÐ¸Ð°ÑÐ¸Ð¹ (Ð´ÐµÐ»ÐµÑÐ¸Ð¹ Ð¸ Ð¸Ð½ÑÐµÑÑÐ¸Ð¹). Ð ÐµÐ·ÑÐ»ÑÑÐ°Ñ - Ð² ÑÐ°Ð±Ð¾ÑÐµ Ð¿ÑÐµÐ´ÑÑÐ°Ð²Ð»ÐµÐ½Ð° ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐ°Ð½Ð½Ð°Ñ Ð¼ÐµÑÐ¾Ð´Ð¸ÐºÐ° Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ Ð¿Ð¾Ð»Ð¸Ð¼ÐµÑÐ°Ð·Ð½Ð¾Ð¹ ÑÐµÐ¿Ð½Ð¾Ð¹ ÑÐµÐ°ÐºÑÐ¸Ð¸ ÐÐ¦Ð  (Ð°Ð»Ð»ÐµÐ»Ñ-ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐµÑÐºÐ°Ñ ÐÐ¦Ð  Ð¸ ÐÐ¦Ð  Ñ Ð°Ð½Ð°Ð»Ð¸Ð·Ð¾Ð¼ ÐºÑÐ¸Ð²ÑÑ Ð¿Ð»Ð°Ð²Ð»ÐµÐ½Ð¸Ñ Ñ Ð²ÑÑÐ¾ÐºÐ¸Ð¼ ÑÐ°Ð·ÑÐµÑÐµÐ½Ð¸ÐµÐ¼) Ð¸ ÐµÐµ Ð¿ÑÐ¾Ð²ÐµÑÐºÐ° Ð½Ð° ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½ÑÑ Ð¾Ð±ÑÐ°Ð·ÑÐ°Ñ. Ð¡ÑÐ¼Ð¼Ð°ÑÐ½Ð¾ Ð±ÑÐ»Ð¾ ÑÑÐ¿ÐµÑÐ½Ð¾ Ð¿ÑÐ¾Ð°Ð½Ð°Ð»Ð¸Ð·Ð¸ÑÐ¾Ð²Ð°Ð½Ð¾ 1993 Ð¾Ð±ÑÐ°Ð·ÑÐ° Ð½Ð° Ð½Ð°Ð»Ð¸ÑÐ¸Ðµ Ð¼ÑÑÐ°ÑÐ¸Ð¹.
description: Hereditary factors play an essential role in the development of cancer. It is known that congenital mutations of the XRCC2, CHEK2, BLM, GPRC5A, and NBS1 genes are associated with an increased risk of their development. To determine the role of mutations in these genes, an approach was proposed based on creating a line of genetically modified mice using CRISPR/Cas9 technology. An essential step in this approach is genotyping the obtained animals to form experimental groups and the subsequent experiment on induced oncogenesis. The aim of this thesis is to develop a technique for genotyping transgenic mice and their offspring to identify mutations in the XRCC2, CHEK2, BLM, GPRC5A, and NBS1 genes, manifested as gene variations (deletions and insertions). Result - the paper presents the developed method based on the PCR polymerase chain reaction (allele-specific PCR and PCR with high-resolution melting curve analysis) and its verification on control samples. A total of 1993 samples were successfully analyzed for mutations.